Pelabresib's partial win at ASH was enough to persuade Novartis to pull the acquisition trigger.

The company’s move could be a warning for rivals including GSK, AstraZeneca and Incyte.

Several companies have followed Pfizer into CDK2 inhibitor development, but the jury is out on this field’s promise.

Another KRAS G12D inhibitor hits the clinic, while Zai Lab hopes to banish the spectre of Rova-T. 

MorphoSys, Blueprint and Syndax celebrate a successful ASH; Cogent not so much.

Competitors struggle, while MorphoSys investors see a path forward for pelabresib after all.

Dizal got a lucky break with golidocitinib, and now mid-stage data back the project’s activity in T-cell lymphoma.

Pelabresib’s Manifest-2 trial yields mixed data, but the bad part could render the whole unpalatable.